optimism about gene therapy

Recently there have been several articles published that have expressed optimism about the future of gene therapy because of approvals for drugs like Kalydeco and Glybera.

In this article (with an FDA or a US focus) the author names the FDA approval of Kalydeco as the most significant approval of 2012. Even though this drug treats only 4% of the 70,000 sufferers worldwide it still generated $113M in sales in the first nine months of 2012. As BLT's technology has such a broad application just think how much revenue our own programs and royalties from others will generate.

http://www.forbes.com/sites/matthewherper/2012/12/27/the-most-important-new-drug-of-2012/

There really is a disconnect between the potential value of BLT and the market's perception. We just cannot get the message across unfortunately.